All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 3:1 split | DEC 2024 | DEC 2023 ~1.7:1 split | DEC 2022 | DEC 2021 ~156.5:1 split |
|---|---|---|---|---|---|
| General & Administrative | $50 | $28 | $32 | $29 | $21 |
| Research & Development | $322 | $93 | $94 | $65 | $48 |
| Total Operating Expenses | $372 | $121 | $126 | $93 | $69 |
| Operating Income | -$372 | -$121 | -$126 | -$93 | -$69 |
| Non-Operating | |||||
| Net Interest Expense | $6 | $4 | $8 | $1 | $0 |
| Other Non-Operating Income (Expense) | -$324 | $4 | $8 | $1 | $0 |
| Net Income | |||||
| Net Income | -$696 | -$117 | -$118 | -$92 | -$69 |
| EPS (Basic) | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 |
| EPS (Diluted) | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 |
| Weighted Avg Shares (Basic) | 9.9M | 68.7M | 67.2M | 39.6M | 33.4M |
| Weighted Avg Shares (Diluted) | 9.9M | 68.7M | 67.2M | 39.6M | 33.4M |
| Shares Outstanding | 9.9M | 3.4M | 3.4M | 2.0M | 1.7M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Vor Biopharma (VOR) financials: revenue, profit and margins
Vor Biopharma (VOR) generated about n/a in revenue and $1.4 billion in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Vor Biopharma profitable?+
Yes, Vor Biopharma reported about $1.4 billion in net income over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 26 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 31 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with VOR
Held by ETFs
VOR is in 26 US ETFs. The largest of them, with VOR's weight in each:
Spot a number that looks wrong? Check it in VOR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VOR
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.